Home » Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist From Eli Lilly
Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist From Eli Lilly
Vanda Pharmaceuticals announced that it has acquired an exclusive world-wide license from Eli Lilly to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May